The protective effects of Telmisartan on the cardiovascular system

The protective effects of Telmisartan on the cardiovascular system - The protective effects of Telmisartan on the cardiovascular system

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000331

Enrollment

100

Registered

2006-02-21

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

treatment with Telmisartan treatment with Losartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertension patient

Exclusion criteria

Exclusion criteria: *Secondary hypertension *heart failure *diabetes mellitus *acute myocardial infarction within 6 months *treated with PCI within 6 months *cerebrovascular disease within 3 months *severe renal failure (serum creatinine>3mg/dl *severe hepatic failure *malignant disease

Design outcomes

Primary

Measure	Time frame
blood pressure, cardiovascular clinical event,cardiac hypertrophy, cardiac function, atherosclerosis,insulin resistance, renal function	—

Countries

Japan

Contacts

Public ContactHiroshi Hasegawa

Chiba University Graduate School of Medicine Cardiovascular Science and Medicine

hasegawa-chiba@umin.ac.jp0432227171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026